How are they going to "commercialize" a kit? Is it kit-able, who is going to pay for the PMA (takes years and milllions of dollars). Key to the CLIA product, who is selling it, do they have an oncology sales force? Lots of questions and plenty of competition in this space...e.g. Roche
The stock price is $67. per share and they are projecting $5.00 plus for 2016. They are making changes to continue to grow the company. They make great products and have a great brand to launch from. The management seems to have the experience to make it all come together. What am I missing here?
I know we have back seat drivers on the board. It seems to be the old story of the guy in the mailroom telling everyone that the CEO doesn't know what he is doing.
Good luck to the longs and the management of deck.
end2war is constantly looking for information.
The sad fact though is he doesn't know what to do with them.
Nothing short of a revelation will do it.
The even sadder fact is, even the revelation won't do it.
He'll find more things to doubt and can be swayed by the wind as if nothing has been revealed.
Any idea how many shares Brean holds? Oppenheimer has a whole 140,000 for all its table-pounding. Does Brean follow the advice of its own January-new-hire analyst? Go ahead, look it up.
Does anyone know if this deme-a tranny "thing" does "it" ever actually speak or use any English? I can't even make heads or tails of what that spaz "thing" ever even says? Is this part of the demon world and all? Nurse KARLY has seen the worst of the worst at Dr. Van Nostran's institute- but never as bad as this deme tranny mess thing? Any help would be appreciated? Bunny hugs Friday and kitty fun time weekend a-"head", yeah !! KARLY warming up for frisky time :)) xo
Sentiment: Strong Sell
These numbers are essentially from the same group of patients - those early adopters from February. We know that there has been a normal delay of between 3 and 4 months for a patient to get the appointment, get the spirometry test, and get the insurance stuff then finally the prescription. So someone who decided March 1st they wanted to get on Affrezza in all likelihood has not even gotten the prescription yet. The script numbers are essentially meaningless at this point simply because they are just recycling the identical group of patients. It will be June before the script counts start including the patients added in March, July before they start including those added in April. The July numbers will begin to show the TRUE demand because it should have been growing significantly by April as the spectacular results began really hitting the wires and kicking up a lot of awareness and interest. For now though it is pretty silly to get excited about the numbers because it is pretty much the same static group of patients.
Sentiment: Strong Buy
Google "Vyzkoušeli jsme mobil s externím displejem na stole" to watch the video. Definitely Laser Beam Scanning. This phone would seem to be the product referenced in the below press release.
MicroVision and Major Global Electronics Brand to Collaborate on Display Engine for a Smartphone
Development Activities in 2014 to Support Possible Product Introduction in 2015
June 05, 2014 09:00 AM Eastern Daylight Time
REDMOND, Wash.--(BUSINESS WIRE)--MicroVision, Inc. (NASDAQ:MVIS), a leader in innovative ultra-miniature projection display technology, today announced that it is collaborating with a major global consumer electronics brand to develop a display engine for use in an innovative smartphone product.
Sentiment: Strong Buy
You are so naive. ONCS went through a reverse split to uplift to NASDAQ. And you try to justify INO valuation with that.